Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

Lars Fruergaard Jørgensen might not be a household name, but his company’s drug Ozempic is. And its success has thrust him — ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...

The U.S. Food and Drug Administration declared that the shortage of Novo Nordisk’s NOVO.B5.83%increase; green up pointing triangle weight-loss medications Wegovy and Ozempic has been resolved ...

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...